Reimbursed Care Access in United States

Currently classified federally as a Schedule I substance under the Controlled Substances Act with no FDA approval for general medical use; medical access in the U.S. is limited to FDA‑regulated clinical trials and state programs that have created parallel regulated pathways (e.g., Oregon and Colorado local/regulatory models). Currently active Phase 2/3 programs and breakthrough‑therapy designations have accelerated development, but as of the time of this report psilocybin is not an FDA‑approved prescription medication and remains subject to federal scheduling; a recent federal administrative action (DEA → HHS review of a rescheduling petition) indicates regulatory activity but not an approved medical market. # #

MDMA‑assisted therapy for PTSD is not FDA‑approved for routine clinical care but is the subject of late‑stage regulatory review: MAPS PBC submitted a New Drug Application (NDA) to the FDA for MDMA‑assisted therapy based on Phase 3 data; approval would be required, and DEA rescheduling would likely follow, before broad medical prescribing and insurance reimbursement are possible in the U.S. Until (and unless) the FDA approves the NDA and the DEA reschedules, access is limited to FDA‑regulated clinical trials and expanded access programs if implemented. #

Esketamine (marketed as SPRAVATO) is FDA‑approved for treatment‑resistant depression and certain depressive emergencies and is distributed under a Risk Evaluation and Mitigation Strategy (REMS) that requires administration and monitoring in certified healthcare settings; it is the only ketamine‑class product with an FDA label. The SPRAVATO REMS program is operated by the manufacturer and mandates site certification, patient monitoring for at least two hours post‑dosing, and restricted dispensing—SPRAVATO cannot be dispensed for unsupervised at‑home use. # #

Reimbursement and payer coverage: SPRAVATO is frequently covered by commercial insurers and can be covered under Medicare/Medicaid in individual cases when billed appropriately as a medical procedure/service performed in a certified setting; coverage typically requires documentation of treatment‑resistant depression (prior trials of antidepressants) and prior authorization. Medicare beneficiaries have obtained coverage under Part B or as a covered medical outpatient service in many instances when REMS‑certified administration and medical necessity criteria are documented, though patient OOP costs and plan variations are common—authorization, coding, and site enrollment are practical determinants of reimbursement. # #

Licensed ketamine (racemic ketamine) for anesthesia is lawful; however, off‑label use of ketamine (IV/IM/subcutaneous) for depression, PTSD and other psychiatric indications is commonly practiced in private clinics across the U.S. This use is not FDA‑approved for psychiatric indications (i.e., racemic ketamine has no FDA psychiatric indication), so access is provided as an off‑label medical service with variable insurance reimbursement. Private insurers and Medicare typically do not reimburse routine clinic‑based IV ketamine for depression except in narrow situations where the service can be coded and justified as a covered medical procedure; many clinics therefore operate on an out‑of‑pocket fee model. The FDA has issued safety communications about compounded or non‑approved ketamine nasal preparations and emphasizes that only approved products should be used per labeling; clinics using off‑label IV/IM ketamine must follow standard medical practice and state medical board rules. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research.